Avro­bio makes way for GPCR biotech Tec­ton­ic Ther­a­peu­tic in re­verse merg­er

The path to an IPO looks a lit­tle green­er in biotech these days, but pri­vate star­tups are still eye­ing re­verse merg­ers to land their Nas­daq foot­ing, with Tim Springer’s Tec­ton­ic Ther­a­peu­tic be­ing the lat­est ex­am­ple.

The Boston-area biotech — found­ed by re­peat biotech en­tre­pre­neur and In­sti­tute for Pro­tein In­no­va­tion founder Springer and Har­vard Med­ical School pro­fes­sor An­drew Kruse — will as­sume the pub­lic po­si­tion of gene ther­a­py mak­er Avro­bio, which last sum­mer end­ed de­vel­op­ment short­ly af­ter sell­ing an as­set to No­var­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER